Want to see BTMD full AI Analyst Report?
BTMD Stock Chart & Stats
$2.28
$0.06(2.63%)
At close: 4:00 PM EDT
$2.28
$0.06(2.63%)
Day’s Range― - ―
52-Week Range$1.27 - $4.55
Previous CloseN/A
Volume52.46K
Average Volume (3M)315.30K
Market Cap
$76.67M
Enterprise Value$159.83
Total Cash (Recent Filing)$5.32M
Total Debt (Recent Filing)$108.42M
Price to Earnings (P/E)4.5
Beta1.59
Next Earnings
Aug 05, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding30,331,425
10 Day Avg. Volume335,797
30 Day Avg. Volume315,298
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.39
Price to Sales (P/S)0.42
P/FCF Ratio2.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.75Price Target Upside20.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.32
Revenue Forecast (FY)$190.60M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationBiote’s recent ability to generate positive and sizable operating and free cash flow provides durable funding for operations, working capital and targeted remediation actions. Consistent cash conversion reduces dependence on external financing and supports investment in salesforce expansion and inventory rebuilds over the medium term.
High, Stable Gross MarginsSustained gross margins near 70% reflect product economics in BHRT pellets and supplements, supporting margin resilience even when revenue fluctuates. Durable unit-level profitability gives management room to absorb temporary supply costs while preserving core operating leverage as provider volumes recover over the next several quarters.
Provider-network And Commercial ScalingInvestment in salesforce growth and practitioner training strengthens Biote’s clinic-support model and recurring reorder base. A larger rep force and expanded practitioner onboarding are structural drivers of procedure and supplement demand, creating a scalable distribution engine that typically converts to durable revenue after multi-month ramps.
Bears Say
Negative Shareholders' EquityPersistent negative equity and elevated, steady debt materially constrain financial flexibility and increase refinancing and covenant risk. Negative book equity can limit access to capital, reduce strategic optionality, and magnify downside from operational setbacks, making capital structure a sustained vulnerability.
Stagnant To Down Revenue And Weaker MarginsRevenue stagnation and a meaningful step-down in net margin versus prior-year point to weakening top-line momentum and operating leverage. If procedure volumes and supplement growth don’t sustainably accelerate, earnings power and cash generation could remain muted, limiting reinvestment and deleveraging prospects.
Production Concentration & Recall-driven Supply RiskHeavy reliance on Asteria plus a voluntary pellet recall exposed supply concentration and created incremental costs and third-party mix dilution. Production interruptions and supplier dependence raise structural operational risk, potentially recurring until vertical capacity and quality controls are demonstrably rebuilt.
biote News
BTMD FAQ
What was biote’s price range in the past 12 months?
biote lowest stock price was $1.27 and its highest was $4.55 in the past 12 months.
What is biote’s market cap?
biote’s market cap is $76.67M.
When is biote’s upcoming earnings report date?
biote’s upcoming earnings report date is Aug 05, 2026 which is in 4 days.
How were biote’s earnings last quarter?
biote released its earnings results on May 06, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.048 by $0.012.
Is biote overvalued?
According to Wall Street analysts biote’s price is currently Undervalued.
Does biote pay dividends?
biote does not currently pay dividends.
What is biote’s EPS estimate?
biote’s EPS estimate is 0.03.
How many shares outstanding does biote have?
biote has 30,331,425 shares outstanding.
What happened to biote’s price movement after its last earnings report?
biote reported an EPS of $0.06 in its last earnings report, beating expectations of $0.048. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of biote?
Currently, no hedge funds are holding shares in BTMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
biote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.75 (20.61% Upside)
$2.75 (20.61% Upside)
Blogger Sentiment
Bullish
BTMD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 218.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.84%
Trailing 12-Months
Company Description
biote
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
BTMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: material short-term financial impacts in Q1 driven by a voluntary product recall and associated supply constraints materially reduced revenue, margins and net income. Offsetting these headwinds were notable operational and commercial progress — strong dietary supplement growth (+19.1%), a sizable expansion of the salesforce (to ~120 reps), training of 200+ new practitioners (+16.5% YoY), active remediation at Asteria (second shift and safety stock build), and maintained full-year guidance (revenue > $190M; adjusted EBITDA > $38M). Management expressed confidence that the issues are temporary and expected a return to procedure revenue growth in the second half of 2026, but acknowledged near-term persisting effects into Q2.View all BTMD earnings summariesBTMD Stock 12 Month Forecast
Average Price Target
$2.75
▲(20.61% Upside)
Technical Analysis
Concord Medical Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―
Ownership Overview
9.01% Insiders
9.29% Mutual Funds
0.30% Other Institutional Investors
76.76% Public Companies and
Individual Investors